This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

Sehr geehrte Ärztinnen und Ärzte,

gerne möchten wir Sie mit der Phase III Studie COMPETE zur Behandlung von neuroendokrinen Tumoren gastroenterischen oder pankreatischen Ursprungs (GEP-NET) vertraut machen. Die folgenden Unterseiten enthalten u.a. umfangreiche Informationen zum Studiendesign, zu Einschluss- und Ausschlusskriterien, eine Auflistung der teilnehmenden klinischen Zentren, sowie Informationen zum untersuchten Radiopharmazeutikum und zum Wirkstoff.

Ihr COMPETE Team

Für die Verwendung des Login, müssen Cookies aktiviert sein.

This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

DocCheck Login

Registrieren Sie sich hier auf der ITM-Fachkreise Website